CTLA4 and melanoma: Pioneering clinical results have been obtained in melanoma where response rates with a genetically modified GM-CSF expressing herpes simplex based OV (T-VEC) in the presence of CTLA-4 or PD-1 blockade were promising and even improved in patients treated with OV combination therapy compared to anti-CTLA4 alone [90,165,166].